JP2010511721A5 - - Google Patents

Download PDF

Info

Publication number
JP2010511721A5
JP2010511721A5 JP2009540401A JP2009540401A JP2010511721A5 JP 2010511721 A5 JP2010511721 A5 JP 2010511721A5 JP 2009540401 A JP2009540401 A JP 2009540401A JP 2009540401 A JP2009540401 A JP 2009540401A JP 2010511721 A5 JP2010511721 A5 JP 2010511721A5
Authority
JP
Japan
Prior art keywords
independently
compound
heteroaryl
alkyl
heterocycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009540401A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010511721A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/086220 external-priority patent/WO2008070599A1/en
Publication of JP2010511721A publication Critical patent/JP2010511721A/ja
Publication of JP2010511721A5 publication Critical patent/JP2010511721A5/ja
Withdrawn legal-status Critical Current

Links

JP2009540401A 2006-12-05 2007-12-03 インダゾール化合物 Withdrawn JP2010511721A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87304106P 2006-12-05 2006-12-05
PCT/US2007/086220 WO2008070599A1 (en) 2006-12-05 2007-12-03 Indazole compounds

Publications (2)

Publication Number Publication Date
JP2010511721A JP2010511721A (ja) 2010-04-15
JP2010511721A5 true JP2010511721A5 (enExample) 2011-01-27

Family

ID=39492604

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009540401A Withdrawn JP2010511721A (ja) 2006-12-05 2007-12-03 インダゾール化合物

Country Status (9)

Country Link
US (1) US7825261B2 (enExample)
EP (1) EP2091329A4 (enExample)
JP (1) JP2010511721A (enExample)
KR (1) KR20090127867A (enExample)
CN (1) CN101616587A (enExample)
AU (1) AU2007329480A1 (enExample)
CA (1) CA2671543A1 (enExample)
TW (1) TWI433672B (enExample)
WO (1) WO2008070599A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR074199A1 (es) * 2008-11-20 2010-12-29 Glaxosmithkline Llc Compuesto de 6-(4-pirimidinil)-1h-indazol, composiciones farmaceuticas que lo comprenden y su uso para preparar un medicamento util para el tratamiento o disminucion de la gravedad del cancer.
DE102009049662A1 (de) 2009-10-13 2011-04-14 Bayer Schering Pharma Aktiengesellschaft 2,5-Disubstituierte 2H-Indazole als EP2-Rezeptor-Antagonisten
WO2011074658A1 (ja) 2009-12-18 2011-06-23 田辺三菱製薬株式会社 新規抗血小板薬
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
TW201326154A (zh) 2011-11-28 2013-07-01 拜耳知識產權公司 作為ep2受體拮抗劑之新穎2h-吲唑
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
JP6064062B2 (ja) 2013-03-15 2017-01-18 ファイザー・インク Ampkを活性化させるインダゾール化合物
CN105451737B (zh) 2013-05-23 2018-04-10 拜耳医药股份有限公司 药物组合物及其用途以及所述药物组合物用于按需避孕的施用方法
UY35650A (es) 2013-07-09 2015-02-27 Takeda Pharmaceutical Compuesto heterocíclico
KR101713303B1 (ko) 2015-12-24 2017-03-07 강원대학교산학협력단 2h-인다졸 유도체의 제조방법
GB201617630D0 (en) 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
AU2019227607C1 (en) 2018-02-27 2023-07-20 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
GB201806320D0 (en) 2018-04-18 2018-05-30 Cellcentric Ltd Process
EP3810610A1 (en) 2018-05-18 2021-04-28 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
CN117304191A (zh) 2018-07-05 2023-12-29 因赛特公司 作为a2a/a2b抑制剂的稠合吡嗪衍生物
LT3860998T (lt) 2018-10-05 2024-06-25 Annapurna Bio Inc. Junginiai ir kompozicijos, skirti gydyti būkles, susijusias su apj receptoriaus aktyvumu
EP3876939A4 (en) 2018-11-07 2022-08-10 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
US12509455B2 (en) 2018-11-07 2025-12-30 Dana-Farber Cancer Institute, Inc. Imidazopyridine derivatives and aza-imidazopyridine derivatives as Janus kinase 2 inhibitors and uses thereof
WO2020097396A1 (en) 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Benzimidazole derivatives and aza-benzimidazole derivatives as janus kinase 2 inhibitors and uses thereof
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
JP7880815B2 (ja) * 2019-10-01 2026-06-26 メモリアル スローン-ケタリング キャンサー センター Idタンパク質の小分子阻害剤
CA3156828A1 (en) 2019-10-03 2021-04-08 Dana-Farber Cancer Institute, Inc. Tricyclic kinase inhibitors and uses thereof
TW202204350A (zh) 2020-05-06 2022-02-01 美商雅捷可斯治療公司 作為jak2抑制劑之6-雜芳基氧基苯并咪唑及氮雜苯并咪唑
EP4267574B1 (en) 2020-12-23 2025-04-23 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
CA3234638A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
US12162881B2 (en) 2021-11-09 2024-12-10 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of JAK2

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100338610B1 (ko) * 1996-09-04 2002-05-27 디. 제이. 우드, 스피겔 알렌 제이 인다졸 유도체 및 포스포디에스터라제 (pde) 유형 iv 및 종양괴사인자 (tnf) 생산의 억제제로서 그의 용도
CA2356638A1 (en) * 1998-12-23 2000-07-06 Nps Allelix Corp. Indole and indolizidine derivatives for the treatment of migraine
US7141581B2 (en) * 1999-07-02 2006-11-28 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
AU2002334355A1 (en) * 2001-09-06 2003-03-18 Prochon Biotech Ltd. Protein tyrosine kinase inhibitors
AU2003293376A1 (en) * 2002-12-10 2004-06-30 Imclone Systems Incorporated Anti-angiogenic compounds and their use in cancer treatment
CA2521907A1 (en) * 2003-04-10 2004-10-21 Pfizer Inc. Bicyclic compounds as nr2b receptor antagonists
US7226930B2 (en) * 2003-04-18 2007-06-05 Memory Pharmaceutical Corporation Phosphodiesterase 4 inhibitors
JP2007532658A (ja) * 2004-04-16 2007-11-15 スミスクライン ビーチャム コーポレーション がんの治療方法
EP1799673A1 (en) * 2004-10-15 2007-06-27 Memory Pharmaceuticals Corporation Pyrazole derivatives as phosphodiesterase 4 inhibitors
EP1830853B1 (en) * 2004-12-27 2011-08-10 Novartis AG Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases
EP1945222B1 (en) * 2005-11-02 2012-12-26 Bayer Pharma Aktiengesellschaft Pyrrolo[2,1-f] [1,2,4]-triazin-4-ylamines as igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases

Similar Documents

Publication Publication Date Title
JP2009529540A5 (enExample)
JP2012508252A5 (enExample)
JP2011522789A5 (enExample)
JP2011037841A5 (enExample)
JP2012515776A5 (enExample)
JP2013512915A5 (enExample)
JP2011513410A5 (enExample)
JP2010501534A5 (enExample)
JP2010527913A5 (enExample)
JP2008510828A5 (enExample)
JP2004516314A5 (enExample)
JP2009504764A5 (enExample)
JP2019524883A5 (enExample)
JP2007522220A5 (enExample)
JP2009535358A5 (enExample)
JP2008510770A5 (enExample)
JP2009535462A5 (enExample)
JP2010504908A5 (enExample)
JP2010536766A5 (enExample)
CY1114932T1 (el) Αντιπαρασιτικοι παραγοντες
JP2006505543A5 (enExample)
JP2009536221A5 (enExample)
JP2016505614A5 (enExample)
JP2013515037A5 (enExample)
JP2010501478A5 (enExample)